1. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4262-5. doi: 
10.1016/j.bmcl.2006.05.069. Epub 2006 Jun 5.

Bicyclo[3.1.0]hexyl urea melanin concentrating hormone (MCH) receptor-1 
antagonists: impacting hERG liability via aryl modifications.

McBriar MD(1), Guzik H, Shapiro S, Xu R, Paruchova J, Clader JW, O'neill K, 
Hawes B, Sorota S, Margulis M, Tucker K, Weston DJ, Cox K.

Author information:
(1)Schering-Plough Research Institute, Kenilworth, NJ 07033, USA. 
mark.mcbriar@spcorp.com

Herein, we report the discovery of an effective strategy to modulate liabilities 
related to affinity of previously disclosed bicyclohexane MCHR-1 antagonists for 
the hERG channel. This paper describes one of several strategies incorporated to 
limit hERG binding via modifications of a terminal aryl group in an otherwise 
promising bicyclohexyl urea series.

DOI: 10.1016/j.bmcl.2006.05.069
PMID: 16753297 [Indexed for MEDLINE]
